<DOC>
	<DOCNO>NCT01603355</DOCNO>
	<brief_summary>The investigator research study see tocilizumab ( Actemra ) safe effective use severe refractory non-infectious uveitis . Uveitis inflammation eye cause body 's immune system react eye tissue .</brief_summary>
	<brief_title>Tocilizumab Management Juvenile Idiopathic Arthritis Associated Uveitis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<criteria>Subjects Juvenile Idiopathic Arthritis Subjects visionthreatening autoimmune uveitis . Failure respond methotrexate least one systemic immunosuppressive intolerance medication due side effect . Failure respond include presence one plus great anterior chamber cell eye ; need topical corticosteroid four time either eye ; ocular hypertension glaucoma attributable topical corticosteroid . Subjects bilateral disease . If subject oral corticosteroid , dosage must stable 2 week prior baseline exceed 10 mg per day 2mg/kg/day ( whichever less ) prednisone equivalent . Subjects must willing agree alter dosage oral steroid first 16 week trial . Must chest radiograph within 3 month prior enrollment evidence malignancy , infection fibrosis . Parent guardian must understand voluntarily sign informed consent form . Pediatric subject either gender 217 year time consent . Inability parent guardian provide voluntary consent Major surgery ( include joint surgery ) within 8 week prior screen plan surgery within 12 month follow randomization . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study Pregnant breastfeed Current liver disease , determine Principal Investigator basis history serum study History severe allergic anaphylactic reaction human , humanized murine monoclonal antibody include tocilizumab . Evidence significant uncontrolled concomitant diseases nervous system , renal , hepatic ( patient prior history ALT elevation exclude ) , endocrine , gastrointestinal ( GI ) disorder , Investigator 's opinion , would preclude patient participation . Uncontrolled disease state , asthma , psoriasis inflammatory bowel disease flare commonly treated oral parenteral corticosteroid . Any major episode infection require hospitalization treatment IV antibiotic within 4 week screen oral antibiotic within 2 week prior screen History active mycobacterial infection specie ( include Mycobacterium tuberculosis ) within 2 year prior screen visit . Subjects Mycobacterium tuberculosis infection 2 year prior screen visit allow successful treatment complete least 2 year prior randomization document available verification . Immunization live/attenuated vaccine within 4 week prior baseline Latent Mycobacterium tuberculosis infection indicate positive Purified Protein Derivative [ PPD ] skin test . Subjects positive PPD skin test document completion treatment latent TB eligible . Subjects positive PPD skin test treat documentation completion treatment ineligible . If QuantiFERON® test perform instead PPD test , negative QuantiFERON® test allow study . History incompletely treat Mycobacterium tuberculosis infection indicate Subject 's medical record document incomplete treatment Mycobacterium tuberculosis Subject 's selfreported history incomplete treatment Mycobacterium tuberculosis History recurrent bacterial infection ( least 3 major infection result hospitalization and/or require intravenous antibiotic treatment within past 2 year ) recurrent viral , fungal , mycobacterial , infection ( include limited atypical mycobacterial disease , hepatitis B C , herpes zoster , exclude fungal infection nail bed ) Clinically significant abnormality chest xray ( CXR ) screening . Chest xrays perform within 3 month prior start study drug acceptable . Use investigational medication within 4 week prior start study drug 5 pharmacokinetic/pharmacodynamic halflives ( whichever longer ) History congenital acquire immunodeficiency ( eg , Common Variable Immunodeficiency [ CVID ] ) Hepatitis B surface antigen positive Hepatitis B core antibody positive screen History Human Immunodeficiency Virus ( HIV ) infection Antibodies Hepatitis C screen Malignancy history malignancy ( except treat [ ie , cure ] basalcell skin carcinoma &gt; 3 year prior screen ) Have multiple sclerosis central demyelinate disorder . Presence transplant organ ( exception corneal transplant perform &gt; 3 month prior enrollment ) . History substance abuse ( drug alcohol ) within previous 3 year , history noncompliance medical regimen , condition/circumstance could interfere subject 's adherence protocol requirement . Previous current use alkylating agent ( e.g . chlorambucil cyclophosphamide ) . Treatment etoposide ( VP16 ) within 3 month prior baseline visit . Administration intravenous immunoglobulin treatment active polyarticular disease within 4 week prior baseline visit . Previous treatment cell deplete therapy , include investigational agent ( e.g . antiCD19 antiCD20 ) . Prior stem cell transplant time . TNF blocker use within 8weeks prior enrollment ( Infliximab use within 10 week prior enrollment ) . Laboratory Exclusion criterion ( screen ) : Serum creatinine &gt; 1.5 ULN ( upper limit normal age sex ) ; AST ALT &gt; 1.5 ULN ( upper limit normal age sex ) ; Total bilirubin &gt; 1.3 mg/dL ( &gt; 23 umol/L ) ; Platelet count &lt; 150 x 103/μL ( &lt; 150,000/mm3 ) ; Hemoglobin &lt; 9.0 g/dL ( &lt; 3.7 mmol/L ) ; WBC count &lt; 5,000/mm3 ( &lt; 5.0 x 109/L ) ; Neutrophil count &lt; 2,500/ mm3 ( &lt; 2.5 x 109/L )</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>JIA</keyword>
</DOC>